|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||2.4000 - 2.4000|
|52-week range||2.4000 - 2.4000|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
STRASBOURG, France & LUND, Sweden, October 01, 2021--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will present additional preclinical data on their novel
STRASBOURG, France, September 22, 2021--Regulatory News: TRANSGENE (Paris:TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2021.
STRASBOURG, France, September 22, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.